AstraZeneca appoints former UK minister to board
This article was originally published in Scrip
Executive Summary
Baroness Shriti Vadera, the former parliamentary under-secretary of state for economic competitiveness and enterprise in the UK cabinet office and department for business, innovation & skills in the most recent Labour government, has been appointed to AstraZeneca's board as a non-executive director, with effect from 1 January, 2011. She will also become a member of the board's audit committee. Since leaving government, Baroness Vadera has taken on a number of advisory roles including senior advisory to the Korean presidency of the Group of Twenty (G20), adviser to Temasek Holdings and advisor to the government of Dubai on the restructuring of Dubia World's debt. Baroness Vadera will also become a non-executive director of Australian mining conglomerate BHP Billiton on 1 January, 2011.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.